Article in Molecules (Basel, Switzerland), 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.9field-weighted citation impact, top 27% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
3 citing papers in PubMed, 6 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
10 authors at 6 institutions in 3 countries.
Abhay TiwariCentre for Rural Development & Technology, Indian Institute of Technology (IIT), New Delhi 110016, India.ORCID 0000-0001-9408-7917
Garima SinghCentre for Rural Development & Technology, Indian Institute of Technology (IIT), New Delhi 110016, India.
Gourav ChoudhirCentre for Rural Development & Technology, Indian Institute of Technology (IIT), New Delhi 110016, India.ORCID 0000-0001-6944-4652
Mohit MotiwaleComputational and Synthetic Chemistry Lab., Department of Pharmaceutical Chemistry, Faculty of Pharmacy, VNS Group of Institutions, Bhopal 462044, India.ORCID 0000-0001-6608-1374
Nidhi JoshiDepartment of Pharmacology, University of Minnesota, Minneapolis, MN 55455, USA.
Vasudha SharmaDepartment of Food Technology, Jamia Hamdard, New Delhi 110062, India.ORCID 0000-0001-8004-5759
Rupesh K SrivastavaDepartment of Biotechnology, All India Institute of Medical Sciences (AIIMS), New Delhi 110029, India.ORCID 0000-0002-3323-0713
Satyawati SharmaCentre for Rural Development & Technology, Indian Institute of Technology (IIT), New Delhi 110016, India.ORCID 0000-0003-0626-9783
Marco TutoneDipartimento di Scienze e Tecnologie Biologiche Chimiche e Farmaceutiche, Università degli Studi di Palermo, 90123 Palermo, Italy.ORCID 0000-0001-5059-8686
Pradeep Kumar SingourComputational and Synthetic Chemistry Lab., Department of Pharmaceutical Chemistry, Faculty of Pharmacy, VNS Group of Institutions, Bhopal 462044, India.
Indian Institute of Technology Delhi · INCT Group Of Institutions · INDepartment of Biotechnology · INJamia Hamdard · INUniversity of Minnesota · USUniversity of Palermo · IT
Funding
University of Palermo FFR-D15-161363
6 · The paper itself
Abstract
Vitamin D's role in combating the SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), the virus causing COVID-19, has been established in unveiling viable inhibitors of COVID-19. The current study investigated the role of pre and pro-vitamin D bioactives from edible mushrooms against Mpro and PLpro proteases of SARS-CoV-2 by computational experiments. The bioactives of mushrooms, specifically ergosterol (provitamin D
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Deciphering the Potential of Pre and Pro-Vitamin D of Mushrooms against Mpro and PLpro Proteases of COVID-19: An In Silico Approach. · full record | OpenQuestion